Literature DB >> 14295521

IMMUNOLOGIC COMPETENCE OF PATIENTS WITH PSORIASIS RECEIVING CYTOTOXIC DRUG THERAPY.

W L EPSTEIN, H I MAIBACH.   

Abstract

Entities:  

Keywords:  ALLERGENS; ANILINE COMPOUNDS; ANTIBODY FORMATION; ANTIGEN-ANTIBODY REACTIONS; ANTINEOPLASTIC AGENTS; AZATHIOPRINE; BENZENE; CATECHOL; GERIATRICS; HYPERSENSITIVITY, DELAYED; IMMUNOLOGY; IMMUNOSUPPRESSIVE AGENTS; MERCAPTOPURINE; METHOTREXATE; PHARMACOLOGY; PLAGUE VACCINE; PSORIASIS; THIOGUANINE; TRIETHYLENE MELAMINE; VINBLASTINE

Mesh：

Substances：

Year:  1965        PMID： 14295521     DOI： 10.1001/archderm.1965.01600120031006

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  7 in total

1.  Clinical aspects of T and B lymphocytes in psoriasis.

Authors:  W Gliński; M Haftek; S Obalak; S Jablońska
Journal:  Arch Dermatol Res       Date:  1977-03-25       Impact factor: 3.017

Review 2.  Research into psoriasis--the last decade.

Authors:  S Shuster
Journal:  Br Med J       Date:  1971-07-24

Review 3.  A current review of psoriasis.

Authors:  E M Farber; R P McClintock
Journal:  Calif Med       Date:  1968-06

4.  [Quantitative behavior of immunoglobulins and complement in psoriasis. Importance of immune factors in psoriasis].

Authors:  S Marghescu; O Braun-Falco
Journal:  Arch Klin Exp Dermatol       Date:  1970

5.  Impaired hapten sensitization in patients with autoimmune disease.

Authors:  N Bangsgaard; K Engkilde; T Menné; M Løvendorf; G K Jacobsen; J Olsen; L Skov
Journal:  Clin Exp Immunol       Date:  2011-06-14       Impact factor: 4.330

6.  Quantitative relationships between sensitizing dose of DNCB and reactivity in normal subjects.

Authors:  P S Friedmann; C Moss; S Shuster; J M Simpson
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

7.  Prevalence and relevance of secondary contact sensitizers in subjects with psoriasis.

Authors:  D S Krupashankar; Shakthi R Manivasagam
Journal:  Indian Dermatol Online J       Date:  2012-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.